• Active, not recruiting

NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM

Updated: May 23

NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma


dara smoldering myeloma

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma


The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).


Sponsor

Janssen Research & Development, LLC


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT03301220


Official Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma

First Posted : October 4, 2017


Click here for details on ClinicalTrials.gov

 

Drug: Daratumumab SC: daratumumab + rHuPH20

 

Locations


United States, Arizona

United States, California

United States, Florida

United States, Georgia

United States, Iowa

United States, Louisiana

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Missouri

United States, Nevada

United States, New York

United States, North Carolina

United States, Ohio

United States, Oregon

United States, Pennsylvania

United States, Texas

United States, Washington

Mexico


Canada, Alberta

Canada, Ontario


Argentina

Brazil


Europe

United Kingdom

Czechia

Denmark

France

Germany

Greece

Italy

Netherlands

Norway

Poland

Sweden

Spain

Belgium

Hungary

Russian Federation


Asia

Turkey

Israel

Japan


Australia




Posts Archive